Lupin Launches RaltegravirTablets in US Market Securing Generic Exclusivity

Lupin's entry into the US market with generic Raltegravir 600 mg tablets carries immediate supply-chain and sourcing implications for procurement leads managing HIV antiretroviral portfolios. The launch activates a 180-day exclusivity period, temporarily limiting the competitive field and positioning Lupin as the sole generic alternative to Merck Sharp & Dohme's Isentress® HD Tablets, 600 mg.

The generic tablet has been confirmed bioequivalent to the reference listed drug (RLD), satisfying the 21 CFR Part 314 bioequivalence standard required for ANDA approval. For QA and regulatory affairs leads, the bioequivalence designation signals that substitution at the dispensing level is permissible under standard generic substitution protocols, with no additional clinical bridging required.

The 180-day exclusivity window, awarded under the Hatch-Waxman framework for first-to-file ANDA applicants, reflects Lupin's sustained investment in paragraph IV filings against branded HIV therapies. For plant heads and supply planning teams, the exclusivity period compresses the timeline for demand forecasting: volume uptake is likely to accelerate in the near term before additional generic entrants can qualify and launch.

Raltegravir, an integrase strand transfer inhibitor, remains a component of combination antiretroviral regimens for HIV-1 infection in adults. The 600 mg twice-daily formulation represented Merck's higher-dose presentation under the Isentress HD designation, distinct from the earlier 400 mg formulation. Generic availability at this dose strength broadens formulary options for payers and pharmacy benefit managers operating under cost-containment mandates.

The launch reinforces a pattern of Indian generic manufacturers securing first-to-file positions in the US antiretroviral segment, a category where patent expiry timelines and ANDA exclusivity windows carry direct revenue consequences. Lupin's manufacturing and regulatory infrastructure supporting this approval will face continued scrutiny under routine FDA GMP surveillance as commercial supply scales.

The measurable outcome to track is market share capture within the exclusivity window before the 180-day period lapses and additional ANDA holders become eligible to launch.

Source: Media4Growth via Indian Pharma Post, 2 November 2026.